Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer

CompletedOBSERVATIONAL
Enrollment

27

Participants

Timeline

Start Date

May 11, 2005

Primary Completion Date

August 2, 2012

Study Completion Date

August 2, 2012

Conditions
Breast Cancer
Interventions
OTHER

high performance liquid chromatography

urine analysis

OTHER

laboratory biomarker analysis

The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.

OTHER

mass spectrometry

The urine samples will be analyzed for 40 estrogen metabolites, conjugates and depurinating DNA adducts by UPLC with tandem mass spectrometric detection.

OTHER

medical chart review

Collection of information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease.

Trial Locations (2)

55905

Mayo Clinic Cancer Center, Rochester

68198-6805

Eppley Cancer Center at University of Nebraska Medical Center, Omaha

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Nebraska

OTHER

NCT00569543 - Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer | Biotech Hunter | Biotech Hunter